These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 33738839)

  • 1. Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model.
    Zhao Y; Wang J; Liu WN; Fong SY; Shuen TWH; Liu M; Harden S; Tan SY; Cheng JY; Tan WWS; Chan JKY; Chee CE; Lee GH; Toh HC; Lim SG; Wan Y; Chen Q
    Hepatology; 2021 Sep; 74(3):1395-1410. PubMed ID: 33738839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
    Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
    Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
    Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
    J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
    Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
    BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice.
    Jung KH; Yoo W; Stevenson HL; Deshpande D; Shen H; Gagea M; Yoo SY; Wang J; Eckols TK; Bharadwaj U; Tweardy DJ; Beretta L
    Clin Cancer Res; 2017 Sep; 23(18):5537-5546. PubMed ID: 28533225
    [No Abstract]   [Full Text] [Related]  

  • 7. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
    Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
    Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
    Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
    Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of liver cancer cell-secreted exosomal PSMA5 controls macrophage polarization to restrain cancer progression by blocking JAK2/STAT3 signaling.
    Xie S; Li X; Yan J; Yu H; Chen S; Chen K
    Immun Inflamm Dis; 2024 Feb; 12(2):e1146. PubMed ID: 38415977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
    Zhao Y; Shuen TWH; Toh TB; Chan XY; Liu M; Tan SY; Fan Y; Yang H; Lyer SG; Bonney GK; Loh E; Chang KTE; Tan TC; Zhai W; Chan JKY; Chow EK; Chee CE; Lee GH; Dan YY; Chow PK; Toh HC; Lim SG; Chen Q
    Gut; 2018 Oct; 67(10):1845-1854. PubMed ID: 29602780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.
    Gu FM; Li QL; Gao Q; Jiang JH; Zhu K; Huang XY; Pan JF; Yan J; Hu JH; Wang Z; Dai Z; Fan J; Zhou J
    Mol Cancer; 2011 Dec; 10():150. PubMed ID: 22171994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway.
    Yang S; Yang C; Yu F; Ding W; Hu Y; Cheng F; Zhang F; Guan B; Wang X; Lu L; Rao J
    Cell Death Dis; 2018 Oct; 9(11):1105. PubMed ID: 30377291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-451 acts as a suppressor of angiogenesis in hepatocellular carcinoma by targeting the IL-6R-STAT3 pathway.
    Liu X; Zhang A; Xiang J; Lv Y; Zhang X
    Oncol Rep; 2016 Sep; 36(3):1385-92. PubMed ID: 27461244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircSOD2 induced epigenetic alteration drives hepatocellular carcinoma progression through activating JAK2/STAT3 signaling pathway.
    Zhao Z; Song J; Tang B; Fang S; Zhang D; Zheng L; Wu F; Gao Y; Chen C; Hu X; Weng Q; Yang Y; Tu J; Ji J
    J Exp Clin Cancer Res; 2020 Nov; 39(1):259. PubMed ID: 33234142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
    Ding H; Zhang X; Su Y; Jia C; Dai C
    Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
    Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
    J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA TUG1 interacting with miR-144 contributes to proliferation, migration and tumorigenesis through activating the JAK2/STAT3 pathway in hepatocellular carcinoma.
    Lv J; Kong Y; Gao Z; Liu Y; Zhu P; Yu Z
    Int J Biochem Cell Biol; 2018 Aug; 101():19-28. PubMed ID: 29791864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.